|
|
Volumn 8, Issue 11, 2007, Pages 956-957
|
|
Targeting VEGF receptors in kidney cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ANTINEOPLASTIC AGENT;
AXITINIB;
BEVACIZUMAB;
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
VASCULOTROPIN RECEPTOR;
VON HIPPEL LINDAU PROTEIN;
CANCER MORTALITY;
CANCER RISK;
CANCER SURVIVAL;
CARCINOGENESIS;
CLINICAL TRIAL;
DERMATITIS;
DIARRHEA;
DISEASE FREE SURVIVAL;
DRUG EFFICACY;
DRUG RESPONSE;
DRUG SAFETY;
FATIGUE;
GENE IDENTIFICATION;
GENE MUTATION;
GENETIC CODE;
GENETIC RISK;
HISTOPATHOLOGY;
HOARSENESS;
HUMAN;
HYPERTENSION;
KIDNEY CANCER;
LETTER;
MUTATIONAL ANALYSIS;
NAUSEA;
PRIORITY JOURNAL;
PROTEIN DETERMINATION;
PROTEIN LOCALIZATION;
PROTEIN TARGETING;
SURVIVAL RATE;
SURVIVAL TIME;
CLINICAL TRIALS, PHASE II AS TOPIC;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
IMIDAZOLES;
INDAZOLES;
KIDNEY NEOPLASMS;
MUTATION;
RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;
SIGNAL TRANSDUCTION;
VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;
|
|
EID: 35448955977
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(07)70322-4 Document Type: Letter |
|
Times cited : (14)
|
|
References (10)
|
